Research programme: inflammatory disorder therapeutics - Teva
Alternative Names: ART123; CEP-37248Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Arana Therapeutics
- Developer Cephalon
- Class Antibodies
- Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 17 Feb 2010 Preclinical development is ongoing with Cephalon in the US
- 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon